Evidence map›Paper›PMID 37208772›Full record

ArticleTrials2023

The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care.

Sibel Saya, Patty Chondros, Anastasia Abela, Cathrine Mihalopolous, Mary Lou Chatterton, Jane Gunn, Timothy F Chen, Thomas M Polasek, Elise Dettmann, Rachel Brooks and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 8 institutions in 3 countries.

Sibel SayaDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia. sibel.saya@unimelb.edu.au.ORCID http://orcid.org/0000-0002-4796-6852
Patty ChondrosDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0003-0393-8734
Anastasia AbelaDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0003-2172-3294
Cathrine MihalopolousSchool of Public Health and Preventive Medicine, Monash University Health Economics Group, Monash University, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-7127-9462
Mary Lou ChattertonSchool of Public Health and Preventive Medicine, Monash University Health Economics Group, Monash University, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-4902-9448
Jane GunnDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0001-8836-7525
Timothy F ChenSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.ORCID http://orcid.org/0000-0003-4189-8403
Thomas M Polasek, Certara, Princeton, NJ, USA.ORCID http://orcid.org/0000-0003-1008-5223
Elise DettmannDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0009-0002-0775-4051
Rachel BrooksDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-8484-335X
Michelle KingDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-3508-6559
Luke SpencerDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0003-4153-9048
Pavithran AlphonseDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-7238-685X
Shakira MiltonDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-8510-6351
Georgia RamsayDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-9408-8028
Zoe SiviourDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0001-8573-9979
Jamie LiewDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-9578-1078
Philip LyDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-9828-6750
Matthew ThoenigDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-2059-4753
Raushaan SeychellDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.
Floriana La RoccaDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.
Luke B HessonGenetics Department, Douglass Hanly Moir Pathology, Sonic Healthcare, Sydney, NSW, Australia.
Nydia MejiasTranslational Software, Mercer Island, WA, USA.
Terri SivertsenGenetics Department, Douglass Hanly Moir Pathology, Sonic Healthcare, Sydney, NSW, Australia.
Melanie Anne GaleaGenetics Department, Douglass Hanly Moir Pathology, Sonic Healthcare, Sydney, NSW, Australia.
Chad BousmanDepartment of Medical Genetics, University of Calgary, Calgary, AB, Canada.ORCID http://orcid.org/0000-0001-6303-8696
Jon EmeryDepartment of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-5274-6336
The University of Melbourne · AUDouglass Hanly Moir Pathology · AUMonash University · AUGarvan Institute of Medical Research · AUMercer Island School District · USPrinceton University · USThe University of Sydney · AUUniversity of Calgary · CA

Funding

MRFF MRF1200060
6 · The paper itself

Abstract

backgroundThe evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs.

methodsThe PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18-65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. DISCUSSION: This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care.

trial registrationAustralian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.

Indexed as

Major Depressive DisorderAntidepressive AgentsAustraliaDepressionHumansPharmacogeneticsPrimary Health CareQuality of LifeRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsTreatment OutcomeAntidepressive AgentsSelective Serotonin Reuptake InhibitorsAntidepressantsGeneral practiceMajor depressive disorderMental healthPharmacogenomicsPrimary careRandomised controlled trial

Identifiers

PMID37208772
PMCPMC10197047
OpenAlexW4377138764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.